This study's results contribute to the growing body of knowledge on the role of IFN signaling in bone diseases and pave the way for future research into the development of targeted therapies for OPLL.

"The signaling cascades of type I interferons are initiated by their binding to interferon-alpha1 and interferon-alpha-2," added Zoler, a researcher at the Weizmann Institute of Science in Rehovot ...